Literature DB >> 21482751

Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.

Stefano Sartori1, Roberta Polli, Elisa Bettella, Sara Rossato, Wainer Andreoli, Marilena Vecchi, Lucio Giordano, Patrizia Accorsi, Gabriella Di Rosa, Irene Toldo, Nelia Zamponi, Francesca Darra, Bernardo Dalla Bernardina, Giorgio Perilongo, Clementina Boniver, Alessandra Murgia.   

Abstract

Two genes causally involved in refractory epilepsy with mental retardation, cyclin-dependent kinase-like 5 and aristaless-related homeobox, could account for at least some forms of early onset epileptic encephalopathy that still lack etiological explanation. With the aim of investigating the specific pathogenic involvement of the 2 genes, we have conducted a clinical and molecular study in 80 patients with epileptic encephalopathy of unknown etiology and onset within the first year of life, regardless of the presence of other clinical features or the definition of a precise epileptologic syndrome. A total of 8 different disease-causing mutations were detected in our population, confirming the pivotal role of these genes in the pathogenesis of the epileptic encephalopathies in infancy. Early key clinical and electroencephalographic phenotypical features identified in these patients can contribute to more precise and early diagnoses. This work provides a better phenotypic characterization and more stringent clinical indications for the molecular test.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482751     DOI: 10.1177/0883073810387827

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.

Authors:  Stephanie Fehr; Meredith Wilson; Jenny Downs; Simon Williams; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Gladys Ho; Roberta Polli; Stavroula Psoni; Xinhua Bao; Nick de Klerk; Helen Leonard; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-08-08       Impact factor: 4.246

Review 2.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

3.  CDKL5 and ARX mutations in males with early-onset epilepsy.

Authors:  Ghayda M Mirzaa; Alex R Paciorkowski; Eric D Marsh; Elizabeth M Berry-Kravis; Livija Medne; Asem Alkhateeb; Art Grix; Elaine C Wirrell; Berkley R Powell; Katherine C Nickels; Barbara Burton; Andrea Paras; Katherine Kim; Wendy Chung; William B Dobyns; Soma Das
Journal:  Pediatr Neurol       Date:  2013-05       Impact factor: 3.372

4.  Reinitiation of mRNA translation in a patient with X-linked infantile spasms with a protein-truncating variant in ARX.

Authors:  Ching Moey; Scott Topper; Mary Karn; Amy Knight Johnson; Soma Das; Jorge Vidaurre; Cheryl Shoubridge
Journal:  Eur J Hum Genet       Date:  2015-08-26       Impact factor: 4.246

5.  Unraveling the pathogenesis of ARX polyalanine tract variants using a clinical and molecular interfacing approach.

Authors:  Isabel Marques; Maria João Sá; Gabriela Soares; Maria do Céu Mota; Carla Pinheiro; Lisa Aguiar; Marta Amado; Christina Soares; Angelina Calado; Patrícia Dias; Ana Berta Sousa; Ana Maria Fortuna; Rosário Santos; Katherine B Howell; Monique M Ryan; Richard J Leventer; Rani Sachdev; Rachael Catford; Kathryn Friend; Tessa R Mattiske; Cheryl Shoubridge; Paula Jorge
Journal:  Mol Genet Genomic Med       Date:  2015-02-25       Impact factor: 2.183

6.  Diagnosis and management of epileptic encephalopathies in children.

Authors:  Puneet Jain; Suvasini Sharma; Manjari Tripathi
Journal:  Epilepsy Res Treat       Date:  2013-07-22

7.  CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.

Authors:  Zhenfu Jiang; Tongtong Gong; Hong Wei
Journal:  FEBS Open Bio       Date:  2020-01-21       Impact factor: 2.792

8.  Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.

Authors:  Heather E Olson; Carolyn I Daniels; Isabel Haviland; Timothy A Benke; Annapurna Poduri; Lindsay C Swanson; Caitlin A Greene; Anne Marie M Denny; Scott T Demarest; Elia Pestana-Knight; Xiaoming Zhang; Ahsan N Moosa; Andrea Fidell; Judith L Weisenberg; Bernhard Suter; Cary Fu; Jeffrey L Neul; Alan K Percy; Eric D Marsh
Journal:  J Neurodev Disord       Date:  2021-09-16       Impact factor: 4.025

9.  Analysis of mutations in 7 genes associated with neuronal excitability and synaptic transmission in a cohort of children with non-syndromic infantile epileptic encephalopathy.

Authors:  Anna Ka-Yee Kwong; Alvin Chi-Chung Ho; Cheuk-Wing Fung; Virginia Chun-Nei Wong
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.